Why the study?
Does linagliptin reduce cardiovascular events compared to placebo or active comparators in patients with type 2 diabetes mellitus?
Does linagliptin reduce cardiovascular events compared to placebo or active comparators in patients with type 2 diabetes mellitus?
In a meta-analysis of Phase 3 trials, linagliptin was associated with a significantly lower risk of cardiovascular events compared to placebo or active comparators in patients with type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Supports linagliptin for CV risk reduction in T2DM; extends phase 3 trial data via meta-analysis.
Johansen et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: